RBC names Gilead a top biotech pick based on valuation

A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

David Paul Morris | Bloomberg | Getty Images

Now is a good entry point into Gilead’s stock as the company begins to stabilize, while still trading at a discount to its peers, according to RBC Capital Markets.

The firm named biotechnology company Gilead to its top picks list and maintained its $91 price target, a near 34% upside.

Articles You May Like

Bed Bath & Beyond beefs up legal team ahead of possible bankruptcy filing in New Jersey
Overconfidence can be ‘a pathway to poor portfolio performance,’ says chief investment officer. How to check your ego
Davos elites see a major risk ahead for markets with looming U.S. debt standoff
New SECURE 2.0 Planning Move – 529 To Roth
Watch the Federal Reserve’s Waller speak live on the economy and interest rates

Leave a Reply

Your email address will not be published. Required fields are marked *